Mediators of inflammation in chronic inflammatory bowel disease

Scandinavian Journal of Gastroenterology, Supplement

Volumn 31, Issue 216, 1996, Pages 149-159

  Nielsen, O H ^a   Rask Madsen, J ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Chemotactic factors; Colitis, ulcerative; Complement; Crohn disease; Cytokines; Eicosanoids; Inflammatory bowel disese; Inflammatory mediators; Leukotrienes; Neuropeptides; Nitric oxide; Platelet activating factor; Prostaglandins; Reactive oxygen species

Indexed keywords

COMPLEMENT; ICOSANOID; LEUKOTRIENE; NEUROPEPTIDE; NITRIC OXIDE; PROSTAGLANDIN; REACTIVE OXYGEN METABOLITE; THROMBOCYTE ACTIVATING FACTOR; AUTACOID;

CHEMOTAXIS; CROHN DISEASE; HUMAN; INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS; DENMARK; IMMUNOLOGY; PHYSIOLOGY; RECURRENT DISEASE;

COLITIS, ULCERATIVE; CROHN DISEASE; DENMARK; HUMANS; INFLAMMATION MEDIATORS; RECURRENCE;

EID: 0029932723     PISSN: 00855928     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. Inflammatory intermediaries in inflammatory bowel disease. Int J Color Dis 1989;4:75-90.
2. Targan SR, Shanahan F, editors. Inflammatory bowel disease-from bench to bedside. Baltimore: Williams and Wilkins 1994.
3. Wallace JL, editor. Immunopharmacology of the gastrointestinal system, London: Academic Press, 1993.
4. MacDermott RP, Stenson WF. Inflammatory bowel disease. In: Targan S, Shanahan F, editors. Immunology and immunopathology of the liver and gastrointestinal tract. New York/Tokyo: Igaku-Shoin, 1990:459-86.
5. Rask-Madsen, J. Eicosanoids and their role in the pathogenesis of diarrhoeal diseases. Clin Gastroenterol 1986;15:545-66.
6. 2 concentrations determined by equilibrium in vivo dialysis of faeces in patients with ulcerative colitis and healthy controls. Gut 1984;25:1271-8.
7. 4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 1986;91:837-44.
8. Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. In vivo effects of orally administered prednisolone on prostaglandin and leucotriene production in ulcerative colitis. Gut 1987;28:1095-9.
9. Rampton DS, Collins CE. Review article: thromboxanes in inflammatory bowel disease-pathogenic and therapeutic implications. Aliment Pharmacol Ther 1993;7:357-67.
10. Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. Mediators of the inflammatory reaction. In: Järnerot G, Lennard-Jones J, Truelove S, editors. Inflammatory bowel diseases. Malmö: Corona AB, 1992:149-69.
11. Ahnfelt-Rønne I, Nielsen OH, Christensen A, Langholz E, Binder V, Riis P. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology 1990;98:1162-9.
12. Brynskov J, Nielsen OH, Ahnfelt-Rønne I, Bendtzen K. Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease. Dig Dis 1994.
13. Cominelli F, Nast CC, Clark BD, Schindler R, Lierena R, Eysselei VE. Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 1990;86:972-80.
14. Cominelli F, Nast CC, Duchini A, Lee M. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology 1992;103:65-71.